Effects of aspirin on arylamine N-acetyltransferase activity and DNA adducts in human bladder tumour cells

Journal of Applied Toxicology

Volumn 19, Issue 6, 1999, Pages 389-394

  Yeh, Chin Chung ^a   Chung, Jing Gung ^b   Wu, Hsi Chin ^a   Chang, Huei Ling ^b   Yeh, Feng Tsgh ^b   Hung, Chi Fu ^c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c JEN AI HOSPITAL   (Taiwan)

Author keywords

2 Aminofluorene; Aspirin; Bladder cancer; DNA adduct; N acetyltransferase

Indexed keywords

ACETYLSALICYLIC ACID; ARYLAMINE ACETYLTRANSFERASE; BENZOIC ACID DERIVATIVE; FLUORENE DERIVATIVE;

ARTICLE; BLADDER TUMOR; CONTROLLED STUDY; CYTOSOL; DNA ADDUCT; DOSE RESPONSE; ENZYME INHIBITION; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

2-ACETYLAMINOFLUORENE; 4-AMINOBENZOIC ACID; ACETYLATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYLAMINE N-ACETYLTRANSFERASE; ASPIRIN; CARCINOGENS; CELL LINE; CYTOSOL; DNA ADDUCTS; ENZYME INHIBITORS; HUMANS; KINETICS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0032745464     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1263(199911/12)19:6<389::AID-JAT596>3.0.CO;2-D     Document Type: Article

References (31)

1. W. W. Weber and D. W. Hein, N-Acetylation pharmacogenetics. Pharmacol. Rev. 37, 25-79 (1985).
2. E. C. Miller and J. A. Miler, Searches for the ultimate chemical carcinogens and their reaction with cellular macromolecules. Cancer 47, 2327-2345 (1981).
3. H. G. Neumann, The role of DNA damage in chemical carcinogenesis of aromatic amines. J. Cancer Res. Clin. Oncol. 112, 100-106 (1986).
4. R. A. Cartwright, R. W. Glasham, H. J. Rogers, R. A. Ahmed, D. Barham-Hall, E. Higgens and M. A. Kahn, Role of N-acetyltransferase phenotype in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2, 842-846 (1982).
5. N. P. Lang, D. Z. J. Chu, C. F. Hunter, D. C. Kendall, T. J. Flammang and F. F. Kadlubar, Role of aromatic amines acetyltransferase in human colorectal cancer. Arch. Surg. 121, 1259-1261 (1986).
6. K. F. llett, B. M. David, P. Detchon, W. M. Castledon and R. Kwa, Acetylator phenotype in colorectal carcinoma. Cancer Res. 47, 1466-1469 (1987).
7. R. B. Hayes, N. Rothman, F. Broly, N. Caporaso, P. Feng, X. You, S. Yin, R. L. Woosley and U. A. Meyer, N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14, 675-678 (1993).
8. T. J. Flammang, D. W. Hein, G. Talaska and F. F. Kadlubar, N-Hydroxyarylamine O-acetyltransferase and its relationship to aromatic amine N-acetyltransferase polymorphism in the inbred hamster and in human tissue cytosol. In Carcinogenic and Mutagenic Responses to Aromatic Amines and Nitroarenes, ed. by C. King, D. Schuetzle, and L. Romano, pp. 137-148. Elsevier, New York (1988).
9. W. G. Kirlin, A. Andrews, F. Ogolla, T. Yerokun, R. J. Ferguson and D. W. Hein, Comparison of the polymorphic expression of N-acetyltransferase activity in human colon and bladder cytosol. Proc. Am. Assoc. Cancer Res. 30, 160-166 (1989).
10. W. G. Kirlin, A. Trinidad, T. Yerokun, F. Ogolla, R. J. Ferguson, A. F. Andrews, P. K. Brady and D. W. Hein, Polymorphic expression of AcCoA-dependent arylamine N-acetyltransferase and AcCoA-dependent O-acetyltransferase activation of N-hydroxyarylamines by human bladder cytosol. Cancer Res. 49, 2448-2454 (1989).
11. M. Binder and P. Zeiller, Antiphlogistic effect of salicyclic acid and its derivatives (in German). Fortsch Med. 111, 530-532 (1993).
12. H. Darius and J. Meyer, Acetylsalicyclic acid in unstable angina, after coronary revascularization and in prevention of cardiac thromboembolism (in German). Z. Kardiol. 81 (Suppl. 4), 177-184 (1992).
13. H. Schrodek and K. Schror, Clinical pharmacology of acetylsalicyclic acid (in German). Z. Kardiol. 81 (Suppl. 4), 171-175 (1992).
14. E. A. Daigneault, R. C. Harndy, K. E. Ferslew, P. J. Rice, J. Singh, L. M. Harvill and J. H. Kalbfleisch, Investigation of the influence of acetylsalylic acid on the steady state of long-term therapy with theophylline in elderly male patients with normal renal function. J. Clin. Pharmacol. 34, 86-90 (1994).
15. B. S. Reddy, C. V. Rao, A. Rivenson and G. Kelloff, Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14, 1493-1497 (1993).
16. J. G. Chung, Effects of aspirin on the in vitro and in vivo acetylation of 2-aminofluorene in the rat. J. App. Toxicol. (manuscript submitted) (1999).
17. J. G. Chung, W. W. Wang, G. W. Chen, L. T. Wu, J. M. Lai and C. H. Tsai, Kinetics of arylamine N-acetyltransferase in tissues from human colon tumor. Medical Journal of China Medical College Hospital 2, 81-92 (1997).
18. J. G. Chung, G. N. Levy and W. W. Weber, Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6. A-Nats slow acetylator congenic mice. Drug Metab. Dispos. 21, 1057-1063 (1993).
19. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
20. W. W. Cleland, The statistical analysis of enzyme kinetic data. Adv. Enzymol. 29, 1-32 (1967).
21. G. N. Levy, J. G. Chung and W. W. Weber, 2-Aminofluorene metabolism and DNA adduct formation by mononuclear leukocytes from rapid and slow acetylator mouse strains. Carcinogenesis 15, 353-357 (1994).
22. G. A. Levy and W. W. Weber, 2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines. Carcinogenesis 10, 705-709 (1989).
23. C. A. McQueen, C. J. Maslansky, I. B. Glowinski, S. B. Crescenzi, W. W. Weber and G. M. Williams, Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes. Proc. Natl. Acad. Sci. USA 79, 1269-1272 (1982).
24. J. G. Chung, Affects of garlic components diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity in human bladder tumor cells. Drug Chem. Toxicol. 22, 343-358 (1999).
25. T. Umemura, K. Tokumo, H. Sima, R. Gebhardt, M. C. Poirier and G. M. Williams, Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Lett. 73, 1-10 (1993).
26. R. F. Minchin, K. F. llett, C. H. Teitel, P. T. Reeves and F. F. Kadlubar, Direct O-acetylation of N-hydroxy arylamines by acetylsalicylic acid to form carcinogen-DNA adducts. Carcinogenesis 13, 663-667 (1992).
27. D. Hickman and E. Sim, N-Acetyltransferase polymorphism: comparison of phenotype and genotype in human. Biochem. Pharmacol. 42, 1007-1014 (1991).
28. I. B. Glowinski, H. E. Radtke and W. W. Weber, Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol. Pharmacol. 14, 940-949 (1978).
29. G. M. Lower, T. Nilsson, Jr., C. E. Nelson, H. Wolf, T. E. Gamsky and G. T. Bryan, N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29, 71-79 (1979).
30. F. A. Beland, D. T. Beranek, K. L. Dooley, R. H. Helflich and F. F. Kadlubar, Arylamine-DNA adducts in vitro and in vivo: their role in bacterial mutagenesis and urinary bladder carcinogenesis. Environ. Health Perspect. 49, 125-134 (1983).
31. P. Einisto, M. Watanabe, M. Ishidate and T. Nohmi, Mutagenicity of 30 chemicals in S. typhimurium possessing different nitroreductase or O-acetyltransferase activities. Mutat. Res. 259, 95-102 (1991).